The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms.
Study Design
- 研究类型
- Randomized Controlled Trial
- 样本量
- 8
- 研究人群
- Healthy volunteers eating 420g cooked beans
- 干预措施
- The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. 300 or 1200 GalU
- 对照组
- Placebo
- 主要结局
- The effect of oral alpha-galactosidase on intestinal gas production and gas-rela
- 效应方向
- Positive
- 偏倚风险
- Low
Abstract
Bloating, abdominal distention, and flatulence represent very frequent complaints in functional disorders but their pathophysiology and treatment are largely unknown. Patients frequently associate these symptoms with excessive intestinal gas and the reduction of gas production may represent an effective strategy. The aim was to evaluate the effect of alpha-galactosidase administration, in a randomized double-blind placebo-controlled protocol, on intestinal gas production and gas-related symptoms after a challenge test meal in healthy volunteers. Eight healthy volunteers ingested 300 or 1200 GalU of alpha-galactosidase or placebo during a test meal containing 420 g of cooked beans. Breath hydrogen excretion and occurrence of bloating, abdominal pain, discomfort, flatulence, and diarrhea were measured for 8 hr. The administration of 1200 GalU of alpha-galactosidase induced a significant reduction of both breath hydrogen excretion and severity of flatulence. A reduction in severity was apparent for all considered symptoms, but both 300 and 1200 GalU induced a significant reduction in the total symptom score. Alpha-galactosidase reduced gas production following a meal rich in fermentable carbohydrates and may be helpful in patients with gas-related symptoms.
简要概述
Assessment of the effect of α-galactosidase administration on intestinal gas production and gas-related symptoms after a challenge test meal in healthy volunteers found it helpful in patients with gas- related symptoms.
Used In Evidence Reviews
Similar Papers
Molecular genetics and metabolism · 2005
Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
The American journal of gastroenterology · 2018
Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment.
Clinical biochemistry · 2015
A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase A gene.
Scandinavian journal of gastroenterology · 2016
Does oral α-galactosidase relieve irritable bowel symptoms?
International journal of environmental research and public health · 2021
Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021